Form 4: Axsome Therapeutics COO Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, exercised stock options and sold the resulting shares under a pre-approved 10b5-1 trading plan.
Summary
- On August 9, 2024, Mark L. Jacobson, the Chief Operating Officer of Axsome Therapeutics, exercised stock options to acquire 47,739 shares of common stock at a price of $4.04 per share.
- The exercise was conducted prior to the options' expiration date later this year.
- Following the exercise, Jacobson sold 47,739 shares of Axsome Therapeutics common stock at a price of $84.26.
- The sale was executed under a pre-approved 10b5-1 trading plan.
- After these transactions, Jacobson directly owns 5,783 shares of Axsome Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects routine insider transactions under a pre-existing plan. There is no indication of positive or negative implications for the company.
Industry Context
This filing is a routine disclosure of insider transactions. It is common for executives to exercise stock options and sell shares, often under pre-arranged trading plans like the 10b5-1 plan, to manage their personal finances.
Key Dates
| Date | Description |
|---|---|
| 12/29/2015 | Date stock options became exercisable |
| 08/09/2024 | Date of stock option exercise and share sale |
| 12/29/2024 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.